Jenken Biosciences, Inc.

Jenken Biosciences, Inc. founded in 2003, is a clinical stage specialty pharmaceutical company dedicated to "repurposing" (finding new therapeutic uses for) off- patent, approved drugs. The Company's drug development strategy is to reduce time-to-market and to lower risk and development costs by re-profiling approved drugs. In addition, the company is developing a rich pipeline of novel chemical entities (NCEs) for therapies of chronic liver disease, inflammatory bowel disease, rheumatoid arthritis, and diabetes, as well as organ damage to the kidney and the lung.